Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;197(4):2240-2257.
doi: 10.1007/s12010-024-05103-1. Epub 2024 Dec 24.

Overexpression of miR-328-3p Inhibits Epithelial-Mesenchymal Transition in Prostate Cancer by Downregulating PFN1

ZhenHua Gu  1 , JianZhong Li  1 , YuCheng Yang  1 , Rui Ding  1 , MeiLi Wang  1 , Jian Chen  2
Affiliations

Overexpression of miR-328-3p Inhibits Epithelial-Mesenchymal Transition in Prostate Cancer by Downregulating PFN1

ZhenHua Gu et al. Appl Biochem Biotechnol. 2025 Apr.

Abstract

MicroRNA (miR)-328-3p is believed to have anti-tumor impacts in various human cancers. However, its role in prostate cancer (PCa) is uncertain. In this research, miR-328-3p expression in PCa was reduced. Meanwhile, it was discovered that miR-328-3p directly targeted profilin-1 (PFN1) 3'-untranslated region to negatively modulate PFN1. Elevating miR-328-3p or reducing PFN1 suppressed cell growth, migration, and invasion, and epithelial-mesenchymal transition; overexpression of miR-328-3p or inhibition of PFN1 delayed tumor growth in vivo. Further studies found that PCa patients with advanced T stage or high Gleason score had significantly lower miR-328-3p compared to PCa patients with early stage or low score. In addition, PCa patients with high miR-328-3p had a better prognosis than those with low miR-328-3p. Briefly, this study highlights the clinical and biological role of miR-328-3p as a tumor suppressor miRNA in PCa and explores the downstream mechanisms of miR-328-3p.

Keywords: Cell proliferation; MicroRNA-328-3p; Modulation; Prostate cancer.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics Approval: The present study was approved by the Ethics Committee of Wuxi Traditional Chinese Medicine Hospital (approval number: WX2011695T316) and written informed consent was provided by all patients prior to the study start. All procedures were performed in accordance with the ethical standards of the Institutional Review Board and The Declaration of Helsinki, and its later amendments or comparable ethical standards. All animal experiments were complied with the ARRIVE guidelines and performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The experiments were approved by the Ethics Committee of Wuxi Traditional Chinese Medicine Hospital (approval number: WX2011983T530). Consent to Participate: Written informed consent was obtained from each subject. Consent for Publication: Written informed consent for publication was obtained from all participants. Competing Interests: The authors declare no competing interests.

References

    1. Labbé, M., Hoey, C., Ray, J., Potiron, V., Supiot, S., Liu, S. K., et al. (2020). microRNAs identified in prostate cancer: Correlative studies on response to ionizing radiation. Molecular Cancer, 19(1), 63. - PubMed - PMC - DOI
    1. Nevedomskaya, E., Baumgart, S. J., & Haendler, B. (2018). Recent advances in prostate cancer treatment and drug discovery. International Journal of Molecular Sciences, 19(5). https://doi.org/10.3390/ijms19051359
    1. Sumanasuriya, S., & De Bono, J. (2018). Treatment of advanced prostate cancer-A review of current therapies and future promise. Cold Spring Harbor Perspectives in Medicine, 8(6). https://doi.org/10.1101/cshperspect.a030635
    1. Lv, C., Li, F., Li, X., Tian, Y., Zhang, Y., Sheng, X., et al. (2017). MiR-31 promotes mammary stem cell expansion and breast tumorigenesis by suppressing Wnt signaling antagonists. Nature Communications, 8(1), 1036. - PubMed - PMC - DOI
    1. Zhang, W. C., Chin, T. M., Yang, H., Nga, M. E., Lunny, D. P., Lim, E. K., et al. (2016). Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression. Nature Communications, 7, 11702. - PubMed - PMC - DOI

MeSH terms

LinkOut - more resources